migralgin 10 tab
cipla - domperidone,paracetamol - tab - 10,500;mg - 10
doloversa 250 mg/250 mg/50 mg tabletten
roxithromycin gh roxithromycin 150 mg blister pack
sanofi-aventis australia pty ltd - roxithromycin -
pliaglis 70 mgg + 70 mgg cream
migris life sciences sdn bhd - lidocaine; tetracaine -
roxithromycin scp
southern cross pharma pty ltd - roxithromycin -
roxithromycin sandoz
sandoz pty ltd - roxithromycin -
roxithromycin-ga
actavis pty ltd - roxithromycin -
stocrin
merck sharp & dohme australia pty ltd - efavirenz -
stocrin efavirenz 30mg/ml oral solution bottle
merck sharp & dohme (australia) pty ltd - efavirenz -
phentermine gh phentermine 15 mg sustained release capsule blister pack
lupin australia pty limited - phentermine, quantity: 15 mg - capsule, modified release - excipient ingredients: sodium polystyrene sulfonate; magnesium stearate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; gelatin; ethanol absolute - phentermine gh is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with phentermine gh can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.